2014

Cancer Immunotherapy Meets Oncology

In Honor of Christoph Huber

ISBN: 978-3-319-05103-1 (Print) 978-3-319-05104-8 (Online)

Table of contents (24 chapters)

previous Page of 2
  1. Front Matter

    Pages i-ix

  2. Immunological and Regulatory Framework for Immuno-oncology

    1. Front Matter

      Pages 1-1

    2. No Access

      Book Chapter

      Pages 3-11

      From Basic Immunology to New Therapies for Cancer Patients

    3. No Access

      Book Chapter

      Pages 13-20

      How T Cells Single Out Tumor Cells: “And That Has Made All the Difference…”

    4. No Access

      Book Chapter

      Pages 21-27

      Effects of Regulatory T Cell–Dendritic Cell Interactions on Adaptive Immune Responses

    5. No Access

      Book Chapter

      Pages 29-36

      Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Cancer Vaccines

    6. No Access

      Book Chapter

      Pages 37-51

      Immunoguiding, the Final Frontier in the Immunotherapy of Cancer

    7. No Access

      Book Chapter

      Pages 53-62

      Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress

  3. Immunotherapies

    1. Front Matter

      Pages 63-63

    2. No Access

      Book Chapter

      Pages 65-68

      Reflections on Cancer Vaccines

    3. No Access

      Book Chapter

      Pages 69-87

      Dendritic Cell-Based Cancer Vaccines

    4. No Access

      Book Chapter

      Pages 89-100

      mRNA Vaccination and Personalized Cancer Therapy

    5. No Access

      Book Chapter

      Pages 101-110

      Antibody Therapy in Oncology

    6. No Access

      Book Chapter

      Pages 111-116

      Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation

    7. No Access

      Book Chapter

      Pages 117-126

      The ABCs of T Cell Receptor Gene Therapy

    8. No Access

      Book Chapter

      Pages 127-135

      The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic

  4. Cancer Entities

    1. Front Matter

      Pages 137-137

    2. No Access

      Book Chapter

      Pages 139-154

      Immunotherapy of Malignant Melanoma

    3. No Access

      Book Chapter

      Pages 155-169

      Prostate Cancer Vaccines Generated with the Disruptive RNActive® Technology Follow the Path Paved by Sipuleucel-T and Prostvac-VF

    4. No Access

      Book Chapter

      Pages 171-178

      Recent Developments in the Active Immunotherapy of Renal Cell Cancer

    5. No Access

      Book Chapter

      Pages 179-191

      Current Status of Immunotherapy in Gastroesophageal Cancer

    6. No Access

      Book Chapter

      Pages 193-201

      Non-small Cell Lung Cancer, NSCLC

    7. No Access

      Book Chapter

      Pages 203-209

      Towards More Specificity and Effectivity in the Antileukemia Immune Response

  5. Biomarkers

    1. Front Matter

      Pages 211-211

    2. No Access

      Book Chapter

      Pages 213-220

      Molecular and Metabolic Cues of the Key-Lock Paradigm Dictating Immunogenic Cell Death

previous Page of 2